LONG MINI-FUTURE - BIOGEN IDEC | Delayed Deutsche Boerse AG 11:02:01 2024-06-06 EDT | ||
| 5.44 EUR | -8.26% |
|
| Current month | +23.03% | ||
| 1 month | +42.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 5.44 | -8.26% |
| 24-06-05 | 5.93 | +7.43% |
| 24-06-04 | 5.52 | +2.41% |
| 24-06-03 | 5.39 | +11.83% |
| 24-05-31 | 4.82 | +13.41% |
Delayed Quote Deutsche Boerse AG
Last update June 06, 2024 at 11:02 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VX8LN8 |
| ISIN | DE000VX8LN88 |
| Date issued | 2022-03-11 |
| Strike | 173.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.02 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.1 € |
|---|---|
| Lowest since issue | 1.79 € |
| Spread | 0.03 € |
| Spread % | 0.54% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
236.7
USD
Average target price
284.8
USD
Spread / Average Target
+20.30%
- Stock Market
- Certificates
- Certificat
